# Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects

> **NCT00696904** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 133 (actual)

## Conditions studied

- HCV Infection

## Interventions

- **DRUG:** ABT-333
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00696904
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2009-02
- **Final completion:** —
- **Target enrollment:** 133 (ACTUAL)
- **Last updated:** 2017-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00696904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00696904, "Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00696904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*